Provigil Buyers' Per Se Theory Nixed In Pay-For-Delay Row

A Pennsylvania federal judge on Monday said the generic-drug manufacturers accused of accepting $300 million from Cephalon Inc. to delay generic versions of narcolepsy drug Provigil won't face a per se...

Already a subscriber? Click here to view full article